CC
CSTL icon

Centiva Capital’s Castle Biosciences CSTL Stock Holding History

Centiva Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,802
Closed -$336K – 1633
2025
Q1 		$336K Sell
16,802
-6,213
-27% -$154K 0.01% 1021
2024
Q4 		$613K Buy
23,015
+3,647
+19% +$111K 0.01% 710
2024
Q3 		$552K Buy
19,368
+95
+0.5% +$2.42K 0.01% 1190
2024
Q2 		$420K Buy
19,273
+9,771
+103% +$218K 0.01% 1263
2024
Q1 		$210K Sell
9,502
-3,056
-24% -$66.5K 0.01% 1445
2023
Q4 		$271K Buy
+12,558
New +$221K 0.01% 1260

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Centiva Capital's CSTL Position: Q2 2025 in Review

Centiva Capital sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 16,802 shares — an estimated $336K sold.

Centiva Capital first reported a position in CSTL in Q4 2023 and held it in 6 quarters. The position peaked at $613K in Q4 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Centiva Capital reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 16,802 Castle Biosciences shares in Q2 2025, an estimated $336K.
  • Centiva Capital first reported a position in Castle Biosciences in Q4 2023 and held it in 6 quarters.
  • Centiva Capital's Castle Biosciences position peaked at $613K in Q4 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.